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Abstract: We studied the binding of [I8F]GBR 131 19 { 1-"(4- 
[L8F]fluorophenyl) (phenyl)methoxy]ethyI]-4-(3-phenylpro- 
py1)piperazine) to rat brain with autoradiography after in- 
travenous injection. The rank order of binding was dorsal 
striatum > nucleus accumbens = olfactory tubercle > sub- 
stantia nigra = ventral tegmental area > other areas. Binding 
was blocked by prior injection of dopamine uptake blockers 
but not by injection of dopamine receptor antagonists or drugs 
that bind to the dialkylpiperazine site. Unilateral 6-hydroxy- 
The dopamine (DA) neurotransmitter systems are 
thought to be involved with schizophrenia, psychosis, 
tardive dyskinesias, and various basal ganglia disorders 
(Tarsy and Baldessarini, 1984; Penney and Young, 
1986; Seeman, 1987). The nigrostriatal DA neurons 
have been shown to be destroyed selectively in Parkin- 
son's disease (PD), causing the symptoms of bradyki- 
nesia, rigidity, and tremor (Hornykiewicz and Kish, 
1987). Several groups have attempted to image quan- 
titatively the DA system using positron emission to- 
mography (PET) and various potential markers, in- 
cluding "F- or ' 'C-labeled butyrophenone neuroleptics 
(Wagner et al., 1983; Wong et al., 1984; Arnett et al., 
1985; Perlmutter et al., 1986) or ['LC]raclopride (Farde 
et al., 1986) to mark dopamine D2 receptors, 6- 
[ 'sF]fluorodihydroxyphenylalanine (6-FDOPA) as a 
tracer for DA syntheses (Garnett et a]., 1983; Calne et 
al., 1985; Leenders et al., 1986), and ["Clnomifensine 
as a marker for DA uptake sites (Tedroff et al., 1988). 
The receptor binding experiments thus far have not 
shown significant changes in striatal uptake of DA re- 
ceptor ligands in patients with PD (Hagglund et al., 
1987; Rutgers et al., 1987). Significant decreases in 6- 
FDOPA uptake in PD patients have been reported 
(Garnett et al., 1983; Calne et al., 1985; Leenders et 
al., 1986). 
dopamine lesions of dopamine neurons caused a marked de- 
crease in striatal and nigral binding on the side of the lesion. 
We conclude that intravenous injection of [I8F]GBR 131 19 
provides a useful marker of presynaptic dopamine uptake 
sites. Key Words: Dopamine uptake-["FIGBR 13 1 19-6- 
Hydroxydopamine lesions-Positron emission tomography 
scanning. Ciliax B. J. et al. Imaging the dopamine uptake 
site with ex vivo ["FIGBR 131 19 binding autoradiography 
in rat brain. J. Neurochem. 55, 6 19-623 (I 990). 
The 6-FDOPA results have been difficult to interpret, 
because several phenomena may affect the final uptake 
level in PD (Cumming et al., 1987; Firnau et al., 1987). 
6-FDOPA is taken up by catecholamine neurons and 
is then decarboxylated to form 6-[' sF]fluorodopamine. 
In DA neurons, 6-['8F]fluorodopamine can be pack- 
aged into synaptic vesicles, metabolized by monoamine 
oxidase, or released and metabolized by catecho1-U- 
methyltransferase. In the periphery, 6-FDOPA is me- 
tabolized to 6-['8F]fl~~ro-3-U-methyldihydroxyphe- 
nylalanine, which forms the major radioactive species 
in the blood, at least in primates (Melega et al., 1989). 
In PD, the DA cell loss decreases the uptake capacity 
of the striatum. It is thought that the surviving DA 
neurons greatly upregulate their DA turnover to com- 
pensate for the loss of DA neurons (Hoehn et al., 1976). 
This increased turnover may decrease the amount of 
6-FDOPA that accumulates. Therefore, quantitative 
evaluation of DA neuronal loss in PD may be very 
difficult with 6-FDOPA, because its uptake is influ- 
enced by many parameters, and PET studies are com- 
plicated by the production of radiolabeled metabolites 
(6-[ 18F]fluoro-3-O-methyldihydroxyphenylalanine). 
Although ["Clnomifensine has been used to image 
changes in PD (Tedroff et al., 1988), nomifensine is 
not a site-selective ligand. Its ICso for inhibiting nor- 
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epinephrine uptake into whole brain synaptosomes is 
9 X lo-' M(Schacht and Heptner, 1974). Furthermore, 
nomifensine's sensitivity to intermediate neuronal 
losses is unknown. Thus, there remains a need for a 
marker of dopaminergic neuron degeneration for ap- 
plications in in vivo imaging with PET. 
We have proposed a new DA uptake inhibitor la- 
beled with fluorine-18, [l'F]GBR 131 19 { 1-"(4- 
[ '*F]fluorophenyl) (phenyl)methoxy]ethy1]-4-(3-phen- 
ylpropy1)piperazine) (Kilbourn, 1988; Kilbourn and 
Haka, 1988; Kilbourn et al., 1989a,b), as a potential 
marker for in vivo imaging of DA neurons with PET. 
We report here the application of ex vivo autoradiog- 
raphy to study the regional distribution of [ "FIGBR 
1 3 1 19, the pharmacological specificity of [ "FIGBR 
131 19 for the DA uptake site, and the effects on 
["FIGBR 13 1 19 distribution of selective, unilateral 
dopaminergic neuron destruction with 6-hydroxydo- 
pamine. 
MATERIALS AND METHODS 
Materials 
GBR 13 1 I9 was a gift of Dr. P. Van der Zee (Gist-Brocades, 
Delft, The Netherlands); fluoxetine and nisoxetine, of Dr. 
David Robertson (Eli Lilly, Indianapolis, IN, U.S.A.); cis- 
flupenthixol, of Dr. John Hyttd (H. Lunbeck A/S, Copen- 
hagen, Denmark); nomifesin, of Hoechst-Roussel Pharma- 
ceuticals (Somerville, NJ, U.S.A.); and desipramine, of Mer- 
rill-Dow Research Institute. Xylazine was purchased from 
Mobay Cop.  (Shawnee, KN, U.S.A.), and ketamine was from 
the Parke-Davis Division of Warner Lambert Co. (Moms 
Plains, NJ, U.S.A.). All other compounds were purchased 
from Sigma (St. Louis, MO, U.S.A.). 
Ex vivo autoradiography 
Male Sprague-Dawley rats (weighing 225-450 g) were 
anesthetized with ethyl ether, catheterized via the left femoral 
vein with polyethylene tubing, and placed in plastic restrain- 
ing tubes to recover for at least 2 h (Ciliax et al., 1986). Each 
rat was injected with ["FIGBR 131 19 (0.5-5 mCi) and de- 
capitated 60 min later. The brains were rapidly removed by 
blunt dissection, frozen on dry ice, thin-sectioned (20 pm) 
in a cryostat/microtome, and thaw-mounted on gelatin- 
coated microscope slides. X-ray film (SB-5; Eastman Kodak) 
was exposed to the sections along with "F-calibrated I4C- 
labeled standards for 12 h (Olds et al., 1985). The films were 
transferred to separate cassettes and developed the next day. 
The optical densities of the resultant film images were de- 
termined using a computer-based image-processing system 
(Imaging Research, St. Catherines, Ontario, Canada). Radio- 
activity levels were determined by a computer-generated 
polynomial regression that compared optical densities of the 
areas of interest with those of the radioactive standards. 
Pharmacologic studies 
To evaluate the pharmacology of in vivo [ "FIGBR 13 1 I9 
binding, rats were predosed 30 min before injection of ra- 
diotracer with either saline vehicle or one of several possible 
competitors. The following drugs and doses were injected 
intravenously: GBR 13 I 19, 10 mg/kg (n = 1); fluoxetine, 20 
mg/kg (n = 3); nisoxetine, 5 mg/kg (n = 3); nomifensine, 8 
mg/kg (n = 3); and cis-flupenthixol, 20 mg/kg (n = 2). 
Lesioning 
["FIGBR 13 1 19 was injected into three rats that had been 
given 6-hydroxydopamine lesions of the medial forebrain 
bundle (MFB) and substantia nigra pars compacta (SNc) (Pan 
et al., 1985). To make the lesions, the animals were pretreated 
with desipramine (15 mg/kg), pargyline (50 mg/kg), and 
atropine ( 1 .O mg/kg). Ten minutes later, the rats were anes- 
thetized with xylazine (3.8 mg/kg) and ketamine (77 mg/kg) 
and placed in a David Kopf small-animal stereotaxic appa- 
ratus. The scalp was incised, and the skull was exposed. A 
small hole was made in the cranium with a dentist drill at 
each of the two lesion sites. To lesion the SNc, the coordinates 
used were 5.0 mm posterior to bregma, 2.0 mm lateral of 
the midline, and 7.4 mm below the cranial surface. The co- 
ordinates for the MFB were 3.0, 1 .8, and 8.4 mm, respectively. 
At each site, 10 pg of 6-hydroxydopamine was injected over 
an 8-min period. The lesioned rats were given 3 weeks to 
recover and tested for ipsilateral rotations after 2.5 mg/kg of 
apomorphine i.p. (Ungerstedt, 197 I ) ,  followed by another 2 
weeks of recovery. Only rats that tested positive (>5 rotations/ 
min) were used. 
RESULTS 
The autoradiograms revealed that the radioactivity 
concentrated in classical dopaminergic nerve terminal 
fields in rats injected with [ "FIGBR 13 1 19 (Table 1). 
The rank order of distribution was dorsal striatum 
> nucleus accumbens = olfactory tubercle = SNc/ 
ventral tegmental area > cortex = cerebellum. This 
range of binding encompassed values from 0.4 to 1.5 
nCi/g of brain. The ratio of striatal-to-cerebellar uptake 
was 3: 1. 
Results of the pharmacological studies are given in 
Fig. 1. Excess unlabeled competitors were injected in- 
travenously 30 min before administration of ['*F]GBR 
13 1 19. A 10 mg/kg dose of unlabeled GBR 13 1 19 
blocked striatal uptake. The antidepressant nomifen- 
sine (8 mg/kg), a DA uptake inhibitor (Raiten et al., 
1979), also blocked specific binding in striatum, and 
the norepinephrine and 5-hydroxytryptamine uptake 
inhibitors, nisoxetine (5 mg/kg) and fluoxetine (20 mg/ 
kg), respectively, did not block in vivo binding. cis- 
Flupenthixol, which acts as a D1 antagonist but has 
also been reported to bind to the "dialkylpiperazine 
TABLE 1. Regional distribution of ex vivo 
['8FJGBR 131 19 binding in rat brain 
nCi/g of brain 
Left Right 
______ ~~ 
Dorsal striatum 1.40 f 0.30 1.46 +. 0.31 
Nucleus accumbens 0.94 f 0.20 0.92 k 0.19 
Olfactory tubercle 0.87 f 0.19 0.81 k 0.16 
Substantia nigra/ventral 
tegmental area 0.84 k 0.15 0.80 k 0.13 
Cortex 0.44 f 0.06 
Cerebellum 0.37 f 0.07 
Data are mean k SEM values. 
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FIG. 1. Pharmacology of ex vivo ['8F]GBR 131 19 binding in rat 
brain, shown as the striatum/cerebellum ratio of uptake in rats 
pretreated with saline vehicle, 20 mg/kg of fluoxetine (fluox), 5 
rng/kg of nisoxetine (nisox), 8 rng/kg of nomifensine (nomi), 10 
mg/kg of GBR 13119 (gbr), or 20 mg/kg of cis-Rupenthixol (cis- 
flup). 
site" (Andersen, 1987; Chagraoui et al., 1987), did not 
decrease the striatal/cerebellum ratio. 
Unilateral 6-hydroxydoparnine lesions of the do- 
paminergic nigrostriatal pathway caused significant re- 
ductions ( p  < 0.005 by paired t test) in radioactive 
uptake in dorsal striatum. The levels decreased to those 
of cerebellum (Fig. 2 and Table 2). Binding in nucleus 
accumbens and olfactory tubercle was also significantly 
decreased ( p  < 0.02 by paired t test), and binding in 
SNc was consistently reduced. 
DISCUSSION 
A presynaptic marker for dopaminergic neurons 
would be of considerable value in PET studies of  pa- 
tients with neurological disorders generally ascribed to 
a loss of DA (for example, PD, progressive supranuclear 
palsy, and striatonigral degeneration). Such a marker 
might allow presymptomatic diagnosis, in vivo study 
of the progression of such diseases, and better evalu- 
ation of methods for treatment. 
We have developed [ "FIGBR 13 1 19 as a potential 
ligand for the in vivo study of DA terminals using PET. 
In vitro binding and uptake studies have indicated that 
drugs of  this class [dialk(en)ylpiperazines] bind to and 
inhibit the high-affinity DA uptake site (Bonnet and 
Costentin, 1986; Bonnet et al., 1986; Dawson et al., 
1986; Janowsky et al., 1986, 1987; Andersen, 1987; 
Benmansour et al., 1987; Chagraoui et al., 1987). The 
in vivo regional brain distribution of radioactivity in 
FIG. 2. Autoradiogram of ex vivo ["FIGBR 131 19 binding in a MFB-lesioned rat. Coronal sections pass through (top left) the striatum, 
(top right) the globus pallidus, (bottom left) the substantia nigra, and (bottom right) the cerebellum. Binding in striatum and substantia 
nigra is reduced on the side of the lesion. 
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TABLE 2. Efects of unilateral 6-hydroxydopamine lesions 
of the MFB on regional distribution of ex vivo 
[''FJGBR 13119 binding in rat brain 
nCi/g of brain 
Unlesioned Lesioned 
Dorsal stnatum 2.81 & 1.31 0.91 * 0.20" 
Nucleus accumbens 1.91 kO.76 0.99 k 0.18" 
Olfactory tubercle 1.80 ? 0.75 0.89 +. 0.15' 
Substantia nigra/ventral 
tegmental area 2.46 =k 0.93 1.25 f 0.30 
Cortex 0.91 k 0.18 
Cerebellum 0.85 & 0.18 
Data are mean & SEM values. Values are twice those of Table 1 
" p  < 0.005 by paired t test. 
p < 0.02 by paired t test. 
because twice as much radioactivity was used. 
rats after [18F]GBR 13 119 injection (Table 1 )  is con- 
sistent with the known distribution of dopaminergic 
innervation, with higher levels in striatum, nucleus ac- 
cumbens, olfactory tubercle, and SNc/ventral tegrnen- 
tal area and low levels in cortex and cerebellum. 
The specificity of [18F]GBR 13 119 binding to the 
DA uptake site was examined by preadministration of 
pharmacological doses of various competing drugs. 
Binding of ["FIGBR 131 19 (expressed as striaturn/ 
cerebellum ratios; Fig. 1) was blocked by drugs specific 
for the DA uptake site (GBR 13 1 19 and nomifensine) 
but was not changed after pretreatment with high-af- 
finity and selective serotonin (fluoxetine) or norepi- 
nephrine (nisoxetine) uptake inhibitors or after pre- 
treatment with cis-flupenthixol, a Dl antagonist. The 
ex vivo specificity of this class of compounds for DA 
uptake sites thus agrees with the selectivity shown in 
vitro (Van der Zee et al., 1980; Janowsky et al., 1986). 
The degree of variability is high in these pharma- 
cological results. We believe this variability is inherent 
in work with short-lived isotopes that must be synthe- 
sized separately for each experiment. For example, the 
autoradiographic experiments are similar in results and 
variability to those of our previous dissection experi- 
ments with ['8F]GBR131 19, in which regional brain 
distribution of [ 18F]GBR 13 1 19 was unchanged after 
pretreatment with dopamine D 1 (cis-flupenthixol) and 
dopamine D2 (spiperone) receptor antagonists (Kil- 
bourn, 1988) or pretreatment with nisoxetine or fluox- 
etine but was significantly decreased by pretreatment 
with GBRl3 119 and nomifensine (Kilbourn et al., 
1989a). 
Unilateral 6-hydroxydopamine lesions are a good 
model for in vivo dopaminergic neuron degeneration 
(Ungerstedt, 197 1). If [l8F]GBR 13 1 19 is a marker for 
presynaptic uptake sites, then its binding in striatum 
should be diminished on the side of such a lesion. 
6-Hydroxydopamine lesions of the nigrostriatal 
pathway were confirmed by assays of rotational loco- 
motion following apomorphine injections. Rats testing 
positive should have >95% of the DA neurons elimi- 
nated (Ungerstedt, 1971). [I8F]GBR 131 19 binding in 
lesioned animals was greatly decreased ipsilateral to 
the side of the lesion (Fig. 2). Thus, [I8F]GBR 131 19 
binding sites appear to be presynaptic and could be 
useful markers of viable DA nerve terminals. 
Several reports have cautioned against using GBR 
drugs for in vivo markers, because they bind to the 
"dialkylpiperazine site" in vitro (Andersen et al., 1987; 
Chagraoui et al., 1987; Filloux et al., 1989). This sec- 
ondary site obscured in vitro binding of [3H]GBR 
12935 (the nonfluorinated analog of GBR 13 119) to 
the DA uptake site, effectively masking any detectable 
changes of the DA uptake sites caused by 6-hydroxy- 
dopamine lesions of the MFB. Our results indicate that 
this secondary site may be artifactual, caused by the 
in vitro conditions. After in vivo injections (present 
study; Kilbourn, 1988; Kilbourn et al., 1989b), we see 
good striatal-to-cerebellar binding ratios; binding in 
striaturn is significantly decreased after nigrostriatal le- 
sions; drugs specific for the DA uptake site block striatal 
binding; and 20 mg/kg of cis-flupenthixol, which does 
not bind to the DA uptake site but does bind to the 
"dialkylpiperazine site," does not block [I8F]GBR 
I3 1 19 binding or alter its regional brain distribution. 
These findings strongly suggest that [ 18F]GBR 13 1 19 
binds to the DA uptake site in vivo with good specificity 
and that under in vivo conditions the secondary "di- 
alkylpiperazine site" accounts for a negligible percent- 
age of specific [ I8F]GBR 13 1 19 binding. Another pos- 
sibility is that the fluorine substituent on GBR 13 1 19 
dramatically decreases its affinity for the "dialkylpi- 
perazine site." However, preliminary in vitro binding 
autoradiography experiments using [ I  8F]GBR 13 1 19 
have shown problems similar to those encountered with 
[3H]GBR 12935 in that the binding is largely insensitive 
to mazindol and is not quickly washed away. 
In vivo [I8F]GBR 13 119 binding may be a useful 
presynaptic marker for DA neurons. It is specific for 
the DA uptake site, and [I8F]GBR 13 1 19 binding is 
sensitive to the destruction of nigrostriatal cells. Be- 
cause we also are able to image ["FIGBR 13 1 19's dis- 
tribution in primate brain using PET (Kilbourn et al., 
1989a), we are highly encouraged about its future ap- 
plication in clinical PET studies. 
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